Compare RDY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | EXEL |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 11.1B |
| IPO Year | N/A | 2000 |
| Metric | RDY | EXEL |
|---|---|---|
| Price | $14.13 | $44.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 24 |
| Target Price | $16.90 | ★ $44.73 |
| AVG Volume (30 Days) | 923.2K | ★ 2.5M |
| Earning Date | 01-22-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | 9.95 | ★ 53.55 |
| EPS | 0.79 | ★ 2.38 |
| Revenue | ★ $3,851,623,984.00 | $2,288,218,000.00 |
| Revenue This Year | $6.16 | $9.14 |
| Revenue Next Year | $2.57 | $12.51 |
| P/E Ratio | ★ $17.94 | $18.68 |
| Revenue Growth | ★ 14.10 | 9.93 |
| 52 Week Low | $12.26 | $31.90 |
| 52 Week High | $16.17 | $49.62 |
| Indicator | RDY | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 62.98 |
| Support Level | $13.64 | $43.00 |
| Resistance Level | $14.20 | $44.91 |
| Average True Range (ATR) | 0.17 | 1.07 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 88.39 | 81.25 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.